BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 24666365)

  • 1. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder.
    Zhang Y; Simpson-Durand CD; Standifer KM
    Br J Pharmacol; 2015 Jan; 172(2):571-82. PubMed ID: 24666365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex Differences in Nociceptin/Orphanin FQ Peptide Receptor-Mediated Pain and Anxiety Symptoms in a Preclinical Model of Post-traumatic Stress Disorder.
    Zhang Y; Schalo I; Durand C; Standifer KM
    Front Psychiatry; 2018; 9():731. PubMed ID: 30670988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of nociceptin/orphanin FQ and NOP receptors in the response to acute and repeated restraint stress in rats.
    Delaney G; Dawe KL; Hogan R; Hunjan T; Roper J; Hazell G; Lolait SJ; Fulford AJ
    J Neuroendocrinol; 2012 Dec; 24(12):1527-41. PubMed ID: 22835008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride.
    Muratani T; Minami T; Enomoto U; Sakai M; Okuda-Ashitaka E; Kiyokane K; Mori H; Ito S
    J Pharmacol Exp Ther; 2002 Oct; 303(1):424-30. PubMed ID: 12235279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased nociceptive sensitivity and nociceptin/orphanin FQ levels in a rat model of PTSD.
    Zhang Y; Gandhi PR; Standifer KM
    Mol Pain; 2012 Oct; 8():76. PubMed ID: 23082795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in nociceptin/orphanin FQ levels in rat brain regions after acute and chronic cannabinoid treatment in conjunction with the development of antinociceptive tolerance.
    Ulugol A; Topuz RD; Gunduz O; Kizilay G; Karadag HC
    Fundam Clin Pharmacol; 2016 Dec; 30(6):537-548. PubMed ID: 27371029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The opioid peptide nociceptin/orphanin FQ mediates prostaglandin E2-induced allodynia, tactile pain associated with nerve injury.
    Okuda-Ashitaka E; Minami T; Matsumura S; Takeshima H; Reinscheid RK; Civelli O; Ito S
    Eur J Neurosci; 2006 Feb; 23(4):995-1004. PubMed ID: 16519664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain.
    Scoto GM; Aricò G; Iemolo A; Ronsisvalle S; Parenti C
    Life Sci; 2009 Jul; 85(5-6):206-10. PubMed ID: 19523963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-Alpha as an Initiator of Allodynia and Anxiety-Like Behaviors in a Preclinical Model of PTSD and Comorbid Pain.
    Dib P; Zhang Y; Ihnat MA; Gallucci RM; Standifer KM
    Front Psychiatry; 2021; 12():721999. PubMed ID: 34512420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
    Gavioli EC; Calo' G
    Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia.
    Scoto GM; Aricò G; Ronsisvalle S; Parenti C
    Peptides; 2007 Jul; 28(7):1441-6. PubMed ID: 17628212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exacerbated Headache-Related Pain in the Single Prolonged Stress Preclinical Model of Post-traumatic Stress Disorder.
    Zhang Y; Standifer KM
    Cell Mol Neurobiol; 2021 Jul; 41(5):1009-1018. PubMed ID: 32930941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of anxiety-like behaviors by nociceptin/orphanin FQ (N/OFQ) and time-dependent changes in N/OFQ-NOP gene expression following ethanol withdrawal.
    Aujla H; Cannarsa R; Romualdi P; Ciccocioppo R; Martin-Fardon R; Weiss F
    Addict Biol; 2013 May; 18(3):467-79. PubMed ID: 22804785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Traumatic Brain Injury Induces Nociceptin/Orphanin FQ and Nociceptin Opioid Peptide Receptor Expression within 24 Hours.
    Al Yacoub ON; Zhang Y; Patankar PS; Standifer KM
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation.
    Tamai H; Sawamura S; Takeda K; Orii R; Hanaoka K
    Eur J Pharmacol; 2005 Mar; 510(3):223-8. PubMed ID: 15763246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats.
    Rawls SM; Schroeder JA; Ding Z; Rodriguez T; Zaveri N
    Neuropeptides; 2007 Aug; 41(4):239-47. PubMed ID: 17512052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative study of [(pF)Phe4,Arg14,Lys15]nociceptin/orphanin FQ-NH2 (UFP-102) at NOP receptors in rat periaqueductal gray slices.
    Kuo CJ; Liao YY; Guerrini R; Calo' G; Chiou LC
    Eur J Pharmacol; 2008 Jan; 579(1-3):110-5. PubMed ID: 17976580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation.
    Sliepen SHJ; Korioth J; Christoph T; Tzschentke TM; Diaz-delCastillo M; Heegaard AM; Rutten K
    Br J Pharmacol; 2021 May; 178(9):1995-2007. PubMed ID: 31724155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JTC-801 alleviates mechanical allodynia in paclitaxel-induced neuropathic pain through the PI3K/Akt pathway.
    Huang J; Chen D; Yan F; Wu S; Kang S; Xing W; Zeng W; Xie J
    Eur J Pharmacol; 2020 Sep; 883():173306. PubMed ID: 32603693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.